Heidelberg Engineering and AI Software Partners Present Workflow Solution for Ophthalmic Analytics at EURETINA and ESCRS
Heidelberg Engineering is expanding its healthcare IT portfolio with the introduction of Heidelberg AppWay. This latest addition to the company’s ecosystem offers secure access to ophthalmic software analytics and AI-powered support systems, according to Heidelberg. It will be embedded into the image management platform HEYEX 2, designed to provide a workflow solution that facilitates seamless exchange of ophthalmic image data with AI-driven analysis services to deliver additional clinical insights as well as treatment monitoring tools for enhanced patient care.
“With Heidelberg AppWay, we aim to support clinicians seeking AI-driven solutions to aid their decision making, and researchers interested in innovative analysis tools,” said Krysten Williams, global head of marketing and education at Heidelberg Engineering. “The services of our app partners in combination with the powerful data of our imaging platforms will empower eye care professionals to uncover even more details of the eye.”
For the launch of the gateway solution, Heidelberg Engineering has partnered with AI software companies to provide innovative ophthalmic apps. With Heidelberg AppWay, eye care professionals can access the RetInSight Fluid Monitor, for example. From any practice or clinic, clinicians can send routine images from their SPECTRALIS platform to the cloud service for a detailed, AI-powered analysis of disease activity and therapeutic benefit. While the patient is still on site, they receive a concise Fluid Monitor report indicating fluid type, distribution and quantity—in a completely secure, encrypted environment.
“This seamless workflow provides clinicians with easy access to fluid parameters—the most important biomarkers in the routine monitoring of patients with nAMD,” said Professor Ursula Schmidt-Erfurth, chair of the Department of Ophthalmology and Optometry at the Medical University of Vienna, Austria. “Availability of a fast, precise, and reliable tool will strongly improve quality and workflow in the most challenging therapeutic task in modern ophthalmology, which is the management of neovascular AMD. It will bring our ability to understand and treat disease to a substantially higher level by introducing precision into decision-making.”